Caprock Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Caprock Group's REGN Position: Q2 2026 in Review
Caprock Group reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $225K and leaving 2,437 shares worth $1.52M. The position accounts for 0.03% of the portfolio, ranked #489.
Caprock Group first reported a position in REGN in Q2 2020 and has held it in 23 quarters since. The position peaked at $2.24M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Caprock Group held 2,437 shares of Regeneron Pharmaceuticals worth $1.52M as of Q2 2026.
- Caprock Group sold 331 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $225K.
- Regeneron Pharmaceuticals made up 0.03% of Caprock Group's portfolio in Q2 2026, its #489 holding.
- Caprock Group first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
- Caprock Group's Regeneron Pharmaceuticals position peaked at $2.24M in Q4 2025.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.